The GLP-1 receptor agonists market includes drugs that help in controlling blood glucose levels by stimulating the secretion of insulin from the pancreas. These drugs mimic the effects of the natural hormone glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonists provide effective glycemic control along with the benefit of weight loss by promoting satiety and delayed gastric emptying. The growing prevalence of type 2 diabetes combined with the rising adoption of GLP-1 receptor agonists as an alternative to insulin is promoting the growth of this market substantially.
Global GLP-1 receptor agonist market is estimated to be valued at USD 25.10 Bn in 2024 and is expected to reach USD 55.70 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.1% from 2024 to 2031.
Key players operating in the GLP-1 Receptor Agonist market are Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, GlaxoSmithKline. Novo Nordisk's Victoza (liraglutide) is the most prescribed GLP-1 receptor agonist drug globally. Eli Lilly's Trulicity (dulaglutide) also captures a sizable market share. The rising prevalence of diabetes, growing awareness about the therapeutic benefits of GLP-1 receptor agonists, and increasing obesity rates are fueling demand in the GLP-1 receptor agonist market substantially.
The GLP-1 Receptor Agonist Market Size agonist drugs is growing steadily owing to a rising number of patients with type 2 diabetes worldwide. As per estimations, around 537 million people suffered from diabetes in 2021 globally and the number is projected to rise to 10% of the world's adult population by 2030 and 78 million in the United States. GLP-1 receptor agonists present an effective alternative for glycemic control with the additional benefit of weight loss making them an attractive option, especially for obese diabetic patients.
Major pharmaceutical companies are focusing on geographical expansion to leverage market opportunities. For instance, Novo Nordisk launched Victoza in China in 2011 and has since strengthened its presence in key emerging markets. Eli Lilly also expanded the commercial availability of Trulicity to more than 50 countries. The rising investments in emerging economies by key players will further aid the global expansion of the GLP-1 receptor agonist market during the forecast period.
Market key trends in the GLP-1 receptor agonist segment include the development of once-weekly formulations. Currently available drugs require daily or twice daily injections which affects compliance. Once-weekly formulations offering dosage convenience is an area of active research. Drugs in the pipeline with weekly or monthly administration could capture a sizable share if approved.
Porter’s Analysis
Threat of new entrants: Increasing costs of R&D makes it difficult for new players to enter the market. Also, established brand names will have an advantage over them.
Bargaining power of buyers: Buyers have moderate bargaining power as there are many established players in the market providing substitute products.
Bargaining power of suppliers: Suppliers have moderate bargaining power as there are many suppliers providing active pharmaceutical ingredients (APIs) and other raw materials required for manufacturing of GLP-1 receptor agonists.
Threat of new substitutes: Threat of substitutes is moderate, as there are many established drug classes providing alternative treatment options for diabetes and obesity. However, GLP-1 receptor agonists have advantages over many other options.
Competitive rivalry: Intense as major players compete on basis of product differentiation, innovative drug delivery systems, and aggressive marketing strategies.
Geographical Regions
Currently, North America accounts for the largest share of the global GLP-1 receptor agonist market, in terms of value. This is majorly due to the high prevalence of diabetes and obesity in the region. Availability of favorable reimbursement policies for diabetes drugs also supports market growth in North America.
The Asia Pacific region is poised to witness the fastest growth during the forecast period. This is attributed to rising healthcare expenditure, growing diabetic population, increasing awareness about GLP-1 therapy. Improving access to diagnostic and treatment facilities will further boost adoption of GLP-1 receptor agonists in Asia Pacific.
Get more insights on - GLP-1 Receptor Agonist Market
Unlock More Insights—Explore the Report in the Language You Prefer.
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)